[Current treatment of locally advanced and metastatic prostate cancer]

Wien Med Wochenschr. 2011 Aug;161(15-16):377-81. doi: 10.1007/s10354-011-0014-7.
[Article in German]


Despite the broad use of PSA-testing in western medicine, still an estimated 1/3 of carcinomas of the prostate (PC) are diagnosed in a locally advanced or metastatic stage. In the current treatment-algorithm for locally advanced PC, radical prostatectomy, external beam radiation therapy (with and without hormonal therapy) and primary androgen deprivation are available. In fact, in a majority of patients treatment of this tumor stage will be a multimodal approach, which has to be discussed individually. For metastatic PC hormonal deprivation therapy is still the gold standard. Beside LHRH-agonists, surgical castration and complete androgen deprivation today LHRH-antagonists represent the different therapeutic options in this tumor stage. Effects on natural course of this disease have to be balanced to the side effects of long-term therapy. Castration-resistant PC is not the object of this overview even though there are a variety of new medical interventions emerging for the treatment of this stage of PC.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Algorithms
  • Androgen Antagonists / adverse effects
  • Androgen Antagonists / therapeutic use
  • Antineoplastic Agents, Hormonal / adverse effects
  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Biomarkers, Tumor / blood
  • Combined Modality Therapy
  • Disease Progression
  • Gonadotropin-Releasing Hormone / analogs & derivatives*
  • Gonadotropin-Releasing Hormone / therapeutic use*
  • Humans
  • Lymphatic Metastasis / pathology
  • Male
  • Neoplasm Staging
  • Orchiectomy*
  • Prostate-Specific Antigen / blood
  • Prostatectomy
  • Prostatic Neoplasms / mortality
  • Prostatic Neoplasms / pathology*
  • Prostatic Neoplasms / therapy*
  • Radiotherapy, Adjuvant
  • Randomized Controlled Trials as Topic
  • Survival Rate


  • Androgen Antagonists
  • Antineoplastic Agents, Hormonal
  • Biomarkers, Tumor
  • Gonadotropin-Releasing Hormone
  • Prostate-Specific Antigen